| Literature DB >> 16439521 |
Mark J Cayabyab1, Avi-Hai Hovav, Tsungda Hsu, Georgia R Krivulka, Michelle A Lifton, Darci A Gorgone, Glenn J Fennelly, Barton F Haynes, William R Jacobs, Norman L Letvin.
Abstract
Because the vaccine vectors currently being evaluated in human populations all have significant limitations in their immunogenicity, novel vaccine strategies are needed for the elicitation of cell-mediated immunity. The nonpathogenic, rapidly growing mycobacterium Mycobacterium smegmatis was engineered as a vector expressing full-length human immunodeficiency virus type 1 (HIV-1) HXBc2 envelope protein. Immunization of mice with recombinant M. smegmatis led to the expansion of major histocompatibility complex class I-restricted HIV-1 epitope-specific CD8(+) T cells that were cytolytic and secreted gamma interferon. Effector and memory T lymphocytes were elicited, and repeated immunization generated a stable central memory pool of virus-specific cells. Importantly, preexisting immunity to Mycobacterium bovis BCG had only a marginal effect on the immunogenicity of recombinant M. smegmatis. This mycobacterium may therefore be a useful vaccine vector.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16439521 PMCID: PMC1367151 DOI: 10.1128/JVI.80.4.1645-1652.2006
Source DB: PubMed Journal: J Virol ISSN: 0022-538X Impact factor: 5.103